Status:
UNKNOWN
Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Lymphoid Neoplasm
Eligibility:
All Genders
16-60 years
Phase:
PHASE2
Brief Summary
In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with...
Eligibility Criteria
Inclusion
- lymphoid malignancies
- donor available: HLA matched sibling, unrelated donor or haplo-identical related donor.
- patients with ECOG \<3
Exclusion
- inform consent not provided
- ECOG \>=3
- poor liver function (enzyme \>2N or bilirubin \>2N)
- poor renal function (Scr \>2N)
- poor cardiac function (EF \<45%)
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04897139
Start Date
January 1 2021
End Date
December 1 2024
Last Update
October 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, China, 200025